2012 ASCO Pre-Meeting Video Coverage

Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses:

Crizotinib for Pediatric Patients With ALCL

Research From the 2012 ASCO Meeting

Dr. Markman on PCP Awareness of Long-Term Side Effects

Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses a large survey that will be presented at the 2012 ASCO Annual Conference, focusing on primary care provider (PCPs) awareness of long-term side effects (LEs) in cancer survivors.

View more >>>

Dr. Chapman on BRAF/MEK Combination for Melanoma

Paul B. Chapman, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses combination therapy with dabrafenib and trametinib, two investigational agents for patients with advanced melanoma that have a V600 BRAF mutation.

View more >>>

Leonard G. Gomella, MD, Bernard W. Godwin Jr. professor of prostate cancer and chairman of the Department of Urology, director of Clinical Affairs, Jefferson Kimmel Cancer Center, discusses:

Neoadjuvant Hormonal Therapy Plus Zytiga

The Unique Attributes of Neoadjuvant Zytiga

Dr. Kazmi Discusses Olanzapine for Breakthrough CINV

Shayma Kazmi, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses olanzapine for breakthrough chemotherapy-induced nausea and vomiting.

View more >>>

Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses:

The Dabrafenib/Trametinib Combination

BRAF/MEK Combination Side Effects

<<<

View more from the 2012 ASCO Conference